Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007:1:58.
doi: 10.3332/ecancer.2008.58. Epub 2007 Oct 16.

Resection of colorectal liver metastases following neoadjuvant chemotherapy

A Chiappa  1 , E Bertani, R Biffi, U Pace, G Viale, G Pruneri, G Zampino, N Fazio, F Orsi, G Bonomo, L Monfardini, P Della Vigna, B Andreoni
Affiliations

Resection of colorectal liver metastases following neoadjuvant chemotherapy

A Chiappa et al. Ecancermedicalscience. 2007.

Abstract

Background/aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable, with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection.

Methodology: Between December 1995 and May 2005, 27 patients with colorectal liver metastases (seven males, 20 females, mean age: 58 ± 8 years; range: 40-75) were treated with neoadjuvant chemotherapy. A seven-year survival analysis was performed. Chemotherapy included mainly 5-fluorouracil, leucovorin and either oxaliplatin or irinotecan for a median of eight courses.

Results: A total of 16 patients (59%) had synchronous and 11 (41%) metachronous metastases. During pre-operative chemotherapy, tumour regression occurred in ten cases (37%), stable disease in a further ten patients (37%) and progressive disease developed in seven cases (26%). The five-year overall survival for NACT responders was 64% and only 15% for non-responders (p=0.044).

Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting survival after liver resection for cure.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Survival of 27 patients undergoing liver resection following neoadjuvant chemotherapy for colorectal-cancer liver metastases.
Figure 2:
Figure 2:
Survival of neoadjuvant chemotherapy patients—responders versus non-responders.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Steele G, Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspective. Ann Surg. 1989;210:127–38. doi: 10.1097/00000658-198908000-00001. - DOI - PMC - PubMed
    1. Scheele J. Hepatectomy for liver metastases. Br J Surg. 1993;80(3):274–6. doi: 10.1002/bjs.1800800302. - DOI - PubMed
    1. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984;119(6):647–51. - PubMed
    1. Nordlinger B, Jaeck D, Guiguet M, et al. Surgical resection of hepatic metastases: multicentric retrospective study by the French Association of Surgery. In: Nordlinger B, Jaeck D, editors. Treatment of Hepatic Metastases of Colorectal Cancer. Paris: Springer-Verlag; 1992. pp. 129–46.
    1. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71. doi: 10.1007/BF00316981. - DOI - PubMed

LinkOut - more resources